Abstract
Purpose Staphylococcus aureus causes severe forms of community-acquired pneumonia (CAP), namely staphylococcal pleuropneumonia in young children and staphylococcal necrotising pneumonia in older patients. Methicillin resistance, the Panton-Valentine leukocidin (PVL) toxin, as well as less specific factors have been associated with poor outcome in severe CAP, but their respective roles are unclear.
Methods A prospective multicentre cohort study of severe staphylococcal CAP was conducted in 77 paediatric and adult intensive care units in France between January 2011 and December 2016. After age-clustering, risk factors for mortality, including pre-existing conditions, clinical presentation, laboratory features, strain genetic lineage, PVL, other virulence factors, and methicillin resistance were assessed using univariate and multivariable Cox and LASSO regressions.
Results Of 163 included patients, aged one month to 87 years, 85 (52.1%) had PVL-positive CAP; there were 20 (12.3%) patients aged <3 years (hereafter “toddlers”), among whom 19 (95%) had PVL-positive CAP. The features of PVL-positive CAP in toddlers matched with the historical description of staphylococcal pleuropneumonia, with a lower mortality (n=3/19, 15%) compared to PVL-positive CAP in older patients (n=31/66, 47%). Mortality in older patients was independently predicted by PVL-positivity (hazard ratio 1.81, 95% CI, 1.03 to 3.17) and methicillin resistance (2.37, 95% CI 1.29 to 4.34) independently from S. aureus lineages and the presence of other virulence determinants.
Conclusion PVL was associated with staphylococcal pleuropneumonia in toddlers and was a risk factor for mortality in older patients with severe CAP, independently of methicillin resistance, S. aureus genetic background and other virulence factors.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. GILLET has nothing to disclose.
Conflict of interest: Dr. TRISTAN has nothing to disclose.
Conflict of interest: Dr. Rasigade reports personal fees from MSD, personal fees from Pfizer, grants from bioMérieux, outside the submitted work.
Conflict of interest: Dr. Saadatian-Elahi has nothing to disclose.
Conflict of interest: Dr. BOUCHIAT has nothing to disclose.
Conflict of interest: Dr. Bès has nothing to disclose.
Conflict of interest: Dr. Dumitrescu has nothing to disclose.
Conflict of interest: Dr. Leloire has nothing to disclose.
Conflict of interest: Dr. Dupieux has nothing to disclose.
Conflict of interest: Dr. LAURENT has nothing to disclose.
Conflict of interest: Dr. Lina has nothing to disclose.
Conflict of interest: Dr. Etienne has nothing to disclose.
Conflict of interest: Dr. VANHEMS reports personal fees from ASTELLAS, personal fees from BIOSCIENCES, grants from MSD, personal fees from PFIZER, grants from ANIOS, outside the submitted work.
Conflict of interest: Dr. Argaud has nothing to disclose.
Conflict of interest: Dr. Vandenesch has nothing to disclose.
- Received December 8, 2020.
- Accepted March 31, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org